Treatment of dementia with Lewy bodies and Parkinson's disease dementia
Identifieur interne : 003695 ( Main/Curation ); précédent : 003694; suivant : 003696Treatment of dementia with Lewy bodies and Parkinson's disease dementia
Auteurs : Werner Poewe [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-08.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Alzheimer Disease (therapy), Antipsychotic, Antipsychotic Agents (therapeutic use), Cholinesterase, Cholinesterase Inhibitors (adverse effects), Cholinesterase Inhibitors (therapeutic use), Counseling, DLB, Humans, Lewy Body Disease (drug therapy), Lewy Body Disease (therapy), Lewy body dementia, Nervous system diseases, PDD, Parkinson Disease (drug therapy), Parkinson Disease (therapy), Parkinson disease, Psychoses, Substance-Induced (drug therapy), Psychoses, Substance-Induced (etiology), Serotonin Uptake Inhibitors (therapeutic use), Treatment, antipsychotics, cholinesterase inhibitor.
- MESH :
- chemical , adverse effects : Cholinesterase Inhibitors.
- chemical , therapeutic use : Antipsychotic Agents, Cholinesterase Inhibitors, Serotonin Uptake Inhibitors.
- drug therapy : Lewy Body Disease, Parkinson Disease, Psychoses, Substance-Induced.
- etiology : Psychoses, Substance-Induced.
- therapy : Alzheimer Disease, Lewy Body Disease, Parkinson Disease.
- Counseling, Humans.
Abstract
Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD‐dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug‐induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add‐on treatment with atypical neuroleptics to control drug‐induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20544
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001799
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001799
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002101
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002F32
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002F32
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002F26
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001380
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001380
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001380
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :004D78
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001D73
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000F48
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001C81
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :005159
Links to Exploration step
ISTEX:C9B9F098E1D58A1ADC905DC9169EF4CF501D3082Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of dementia with Lewy bodies and Parkinson's disease dementia</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><country>Autriche</country>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:C9B9F098E1D58A1ADC905DC9169EF4CF501D3082</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20544</idno>
<idno type="url">https://api.istex.fr/document/C9B9F098E1D58A1ADC905DC9169EF4CF501D3082/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001799</idno>
<idno type="wicri:Area/Istex/Curation">001799</idno>
<idno type="wicri:Area/Istex/Checkpoint">002101</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Poewe W:treatment:of:dementia</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16092095</idno>
<idno type="wicri:Area/PubMed/Corpus">002F32</idno>
<idno type="wicri:Area/PubMed/Curation">002F32</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F26</idno>
<idno type="wicri:Area/Ncbi/Merge">001380</idno>
<idno type="wicri:Area/Ncbi/Curation">001380</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001380</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Poewe W:treatment:of:dementia</idno>
<idno type="wicri:Area/Main/Merge">004D78</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:05-0457542</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001D73</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000F48</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001C81</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Poewe W:treatment:of:dementia</idno>
<idno type="wicri:Area/Main/Merge">005159</idno>
<idno type="wicri:Area/Main/Curation">003695</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of dementia with Lewy bodies and Parkinson's disease dementia</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="4"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University of Innsbruck</wicri:regionArea>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-08">2005-08</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">S12</biblScope>
<biblScope unit="supplement">S12</biblScope>
<biblScope unit="page" from="S77">S77</biblScope>
<biblScope unit="page" to="S82">S82</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">C9B9F098E1D58A1ADC905DC9169EF4CF501D3082</idno>
<idno type="DOI">10.1002/mds.20544</idno>
<idno type="ArticleID">MDS20544</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer Disease (therapy)</term>
<term>Antipsychotic</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Cholinesterase</term>
<term>Cholinesterase Inhibitors (adverse effects)</term>
<term>Cholinesterase Inhibitors (therapeutic use)</term>
<term>Counseling</term>
<term>DLB</term>
<term>Humans</term>
<term>Lewy Body Disease (drug therapy)</term>
<term>Lewy Body Disease (therapy)</term>
<term>Lewy body dementia</term>
<term>Nervous system diseases</term>
<term>PDD</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (therapy)</term>
<term>Parkinson disease</term>
<term>Psychoses, Substance-Induced (drug therapy)</term>
<term>Psychoses, Substance-Induced (etiology)</term>
<term>Serotonin Uptake Inhibitors (therapeutic use)</term>
<term>Treatment</term>
<term>antipsychotics</term>
<term>cholinesterase inhibitor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Cholinesterase Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Cholinesterase Inhibitors</term>
<term>Serotonin Uptake Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lewy Body Disease</term>
<term>Parkinson Disease</term>
<term>Psychoses, Substance-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychoses, Substance-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Alzheimer Disease</term>
<term>Lewy Body Disease</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Counseling</term>
<term>Humans</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antipsychotique</term>
<term>Cholinesterase</term>
<term>Démence corps Lewy</term>
<term>Parkinson maladie</term>
<term>Système nerveux pathologie</term>
<term>Traitement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD‐dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug‐induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add‐on treatment with atypical neuroleptics to control drug‐induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data. © 2005 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2005:Poewe W:treatment:of:dementia"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Treatment of dementia with lewy bodies and Parkinson's disease dementia</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Neurology, Medical University of Innsbruck</s1>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0457542</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0457542 INIST</idno>
<idno type="RBID">Pascal:05-0457542</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001D73</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000F48</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001C81</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Poewe W:treatment:of:dementia</idno>
<idno type="wicri:Area/Main/Merge">005159</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Treatment of dementia with lewy bodies and Parkinson's disease dementia</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Neurology, Medical University of Innsbruck</s1>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antipsychotic</term>
<term>Cholinesterase</term>
<term>Lewy body dementia</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Traitement</term>
<term>Démence corps Lewy</term>
<term>Cholinesterase</term>
<term>Antipsychotique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD-dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug-induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add-on treatment with atypical neuroleptics to control drug-induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of dementia with Lewy bodies and Parkinson's disease dementia</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><country>Autriche</country>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:C9B9F098E1D58A1ADC905DC9169EF4CF501D3082</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20544</idno>
<idno type="url">https://api.istex.fr/document/C9B9F098E1D58A1ADC905DC9169EF4CF501D3082/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001799</idno>
<idno type="wicri:Area/Istex/Curation">001799</idno>
<idno type="wicri:Area/Istex/Checkpoint">002101</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Poewe W:treatment:of:dementia</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16092095</idno>
<idno type="wicri:Area/PubMed/Corpus">002F32</idno>
<idno type="wicri:Area/PubMed/Curation">002F32</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F26</idno>
<idno type="wicri:Area/Ncbi/Merge">001380</idno>
<idno type="wicri:Area/Ncbi/Curation">001380</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001380</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Poewe W:treatment:of:dementia</idno>
<idno type="wicri:Area/Main/Merge">004D78</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of dementia with Lewy bodies and Parkinson's disease dementia</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="4"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University of Innsbruck</wicri:regionArea>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-08">2005-08</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">S12</biblScope>
<biblScope unit="supplement">S12</biblScope>
<biblScope unit="page" from="S77">S77</biblScope>
<biblScope unit="page" to="S82">S82</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">C9B9F098E1D58A1ADC905DC9169EF4CF501D3082</idno>
<idno type="DOI">10.1002/mds.20544</idno>
<idno type="ArticleID">MDS20544</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer Disease (therapy)</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Cholinesterase Inhibitors (adverse effects)</term>
<term>Cholinesterase Inhibitors (therapeutic use)</term>
<term>Counseling</term>
<term>DLB</term>
<term>Humans</term>
<term>Lewy Body Disease (drug therapy)</term>
<term>Lewy Body Disease (therapy)</term>
<term>PDD</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (therapy)</term>
<term>Psychoses, Substance-Induced (drug therapy)</term>
<term>Psychoses, Substance-Induced (etiology)</term>
<term>Serotonin Uptake Inhibitors (therapeutic use)</term>
<term>antipsychotics</term>
<term>cholinesterase inhibitor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Cholinesterase Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Cholinesterase Inhibitors</term>
<term>Serotonin Uptake Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lewy Body Disease</term>
<term>Parkinson Disease</term>
<term>Psychoses, Substance-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychoses, Substance-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Alzheimer Disease</term>
<term>Lewy Body Disease</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Counseling</term>
<term>Humans</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD‐dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug‐induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add‐on treatment with atypical neuroleptics to control drug‐induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data. © 2005 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003695 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003695 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:C9B9F098E1D58A1ADC905DC9169EF4CF501D3082 |texte= Treatment of dementia with Lewy bodies and Parkinson's disease dementia }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |